en
Scientific article
English

Impact of a sirolimus/tacrolimus-based immunosuppressive regimen on kidney function after islet transplantation

Published inTransplantation proceedings, vol. 37, no. 2, p. 1326-1327
Publication date2005
Abstract

Islet transplantation is gaining recognition as a therapeutic option for selected diabetic patients. The immunosuppressive regimen based on sirolimus/low-dose tacrolimus is considered a major breakthrough that allowed considerable improvement in graft survival. A high incidence of side effects associated with such a regimen has been reported in the literature, but this immunosuppressive protocol is generally considered safe or even protective to the kidney. Herein, we analyze the impact of the sirolimus/low-dose tacrolimus-based protocol on kidney function.

Keywords
  • Creatinine/metabolism
  • Diabetes Mellitus, Type 1/drug therapy/surgery
  • Drug Therapy, Combination
  • Follow-Up Studies
  • Humans
  • Hypoglycemic Agents/therapeutic use
  • Immunosuppressive Agents/therapeutic use
  • Insulin/therapeutic use
  • Islets of Langerhans Transplantation/immunology/methods/physiology
  • Kidney Function Tests
  • Sirolimus/therapeutic use
  • Tacrolimus/therapeutic use
  • Treatment Outcome
Citation (ISO format)
ANDRES, Axel et al. Impact of a sirolimus/tacrolimus-based immunosuppressive regimen on kidney function after islet transplantation. In: Transplantation proceedings, 2005, vol. 37, n° 2, p. 1326–1327. doi: 10.1016/j.transproceed.2004.12.040
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0041-1345
655views
0downloads

Technical informations

Creation05/30/2014 10:49:00 AM
First validation05/30/2014 10:49:00 AM
Update time03/14/2023 9:16:58 PM
Status update03/14/2023 9:16:57 PM
Last indexation01/16/2024 10:48:08 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack